65141-04-0

Basic information

• Product Name: Carbamic acid, (4-fluorophenyl)-, phenyl ester
• CAS NO: 65141-04-0
• Molecular Formula: C13H10FNO2
• Molecular Weight: 231.226
• Mol File: 65141-04-0.mol
• Article Data: 21

Chemical Properties

• CAS DataBase Reference: Carbamic acid, (4-fluorophenyl)-, phenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (4-fluorophenyl)-, phenyl ester(65141-04-0)
• EPA Substance Registry System: Carbamic acid, (4-fluorophenyl)-, phenyl ester(65141-04-0)

Safety Data

• Hazardous Substances Data: 65141-04-0(Hazardous Substances Data)

Upstream product

• 1195-45-5 para-fluorophenyl isocyanate 
• 108-95-2 phenol 
• 371-40-4 4-fluoroaniline 
• 84882-85-9 N-(4-fluorophenyl)-1H-imidazole-1-carboxamide 
• 1885-14-9 phenyl chloroformate 

Downstream Products

• 279241-45-1 [3-(acridin-9-yl)amino-5-amino]benzyl N-(4-fluorophenyl) carbamate 
• 1198565-08-0 N-(4-fluorophenyl)-1H-indole-1-carboxamide 
• 5083-03-4 4-methyl-N-(4-fluorophenyl)benzamide 
• 1596368-63-6 (E)-1-{[(7-dimethylamino)-2-oxo-2H-chromen-3-yl]methylidene}-4-(4-fluorophenyl)semicarbazone 
• 1350899-04-5 (E)-1-(4-hydroxy-3-methoxybenzylidene)-4-(4-fluorophenyl)semicarbazone 

Relevant articles and documents

Ligand-based optimization to identify novel 2-aminobenzo[d]thiazole derivatives as potent sEH inhibitors with anti-inflammatory effects

Inhibition of the soluble epoxide hydrolase (sEH) is a promising new therapeutic approach in the treatment of inflammation. Driven by the in-house database product lead 1, a hybridization strategy was utilized for the design of a series of novel benzo [d]thiazol derivatives. To our delight, D016, a byproduct of compound 9, was obtained with an extraordinarily low IC50 value of 0.1 nM but poor physical and chemical properties. After removal of a non-essential urea moiety or replacement of the urea group by an amide group, compounds 15a, 17p, and 18d were identified as promising sEH inhibitors, and their molecular binding modes to sEH were constructed. Furthermore, compounds 15a and 18d exhibited more effective in vivo anti-inflammatory effect than t-AUCB in carrageenan-induced mouse paw edema. Compound 15a also showed moderate metabolic stability with a half-time of 34.7 min. Although 18d was unstable in rat liver microsomes, it might be a “prodrug”. In conclusion, this study could provide valuable insights into discovery of new sEH inhibitors, and compounds 15a and 18d were worthy of further development as potential drug candidates to treat inflammation.

Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3

Hybridization strategy is an effective strategy to obtain multi-target inhibitors in drug design. In this study, we assembled the pharmacophores of momelotinib and tandutinib to get a series of 4-piperazinyl-2-aminopyrimidine derivatives. All compounds were tested for the inhibition of JAK2 and FLT3 enzymes, of which, compounds with potent enzyme activities were assayed for antiproliferative activities against three cancer cell lines (HEL, MV4-11, and HL60). The structure-activity relationship studies were conducted through variations in two regions, the “A” phenyl ring and “B” phenyl ring. Compound 14j showed the most balanced in vitro inhibitory activity against JAK2 and FLT3 (JAK2 IC50 = 27 nM, FLT3 IC50 = 30 nM), and it also showed potent inhibition against the above tested cell lines. In the cellular context, 14j strongly induced apoptosis by arresting cell cycle in the G1/S phase, and was selected as a promising JAK2/FLT3 dual inhibitor.

Tyrosine kinase inhibitor and application thereof

The invention discloses a tyrosine kinase inhibitor. A chemical name of the tyrosine kinase inhibitor is 1-(2-chloro-4-((6,7-dimethoxyquinoline-4-yl)oxy)phenyl)-3-(4-fluorophenyl)carbamide and a structure is shown as a formula (I). Meanwhile, the inventio